Patent intelligence · US
US 9890213
Methods for the treatment of B cell-mediated inflammatory diseases
Methods for the treatment of B cell-mediated inflammatory diseases
Patent details — US 9890213
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 13, 2018
- Expiration
- Feb 8, 2038
- Applicant
- VACCINEX, INC.
- Claims
- 15
- CPC classes
- A61K, A61K2039/505, A61P, A61P37/00
Quick answer
US 9890213 (Methods for the treatment of B cell-mediated inflammatory diseases) is held by VACCINEX, INC.. Status: granted. Granted Feb 13, 2018. Expires Feb 8, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- VACCINEX, INC.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K2039/505, A61P, A61P37/00, A61P37/06
More from VACCINEX, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12201719
Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
granted -
US 12070500
Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis
granted -
US 12006364
Anti-CD100 antibodies and methods for using the same
granted -
US 12006365
Human anti-semaphorin 4D antibody
granted -
US 11981730
Anti-CXCL13 antibodies and methods of using the same
granted -
US 11859000
Anti-CCR8 antibodies and uses thereof
granted -
US 11660330
Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
granted -
US 11597765
Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
granted
Frequently asked questions
What is US patent 9890213?
US 9890213 (Methods for the treatment of B cell-mediated inflammatory diseases) is held by VACCINEX, INC.. Status: granted. Granted Feb 13, 2018. Expires Feb 8, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9890213?
VACCINEX, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 41 pharmaceutical patents for this assignee.
When does US 9890213 expire?
Our index shows an expiration date of Feb 8, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.